Show simple item record

dc.contributor.authorFelmlee, DJ
dc.contributor.authorCoilly, A
dc.contributor.authorChung, RT
dc.contributor.authorSamuel, D
dc.contributor.authorBaumert, TF
dc.date.accessioned2017-12-04T15:46:06Z
dc.date.available2017-12-04T15:46:06Z
dc.date.issued2016-06
dc.identifier.issn1473-3099
dc.identifier.issn1474-4457
dc.identifier.urihttp://hdl.handle.net/10026.1/10362
dc.descriptionpublisher: Elsevier articletitle: New perspectives for preventing hepatitis C virus liver graft infection journaltitle: The Lancet Infectious Diseases articlelink: http://dx.doi.org/10.1016/S1473-3099(16)00120-1 content_type: article copyright: © 2016 Elsevier Ltd. All rights reserved.
dc.description.abstract

Hepatitis C virus (HCV) infection is a leading cause of end-stage liver disease that necessitates liver transplantation. The incidence of virus-induced cirrhosis and hepatocellular carcinoma continues to increase, making liver transplantation increasingly common. Infection of the engrafted liver is universal and accelerates progression to advanced liver disease, with 20-30% of patients having cirrhosis within 5 years of transplantation. Treatments of chronic HCV infection have improved dramatically, albeit with remaining challenges of failure and access, and therapeutic options to prevent graft infection during liver transplantation are emerging. Developments in directed use of new direct-acting antiviral agents (DAAs) to eliminate circulating HCV before or after transplantation in the past 5 years provide renewed hope for prevention and treatment of liver graft infection. Identification of the ideal regimen and use of DAAs reveals new ways to treat this specific population of patients. Complementing DAAs, viral entry inhibitors have been shown to prevent liver graft infection in animal models and delay graft infection in clinical trials, which shows their potential for use concomitant to transplantation. We review the challenges and pathology associated with HCV liver graft infection, highlight current and future strategies of DAA treatment timing, and discuss the potential role of entry inhibitors that might be used synergistically with DAAs to prevent or treat graft infection.

dc.format.extent735-745
dc.format.mediumPrint
dc.languageen
dc.language.isoen
dc.publisherElsevier BV
dc.subjectAntiviral Agents
dc.subjectDisease Progression
dc.subjectHepacivirus
dc.subjectHepatitis C
dc.subjectHepatitis C, Chronic
dc.subjectHumans
dc.subjectIncidence
dc.subjectLiver Cirrhosis
dc.subjectLiver Transplantation
dc.subjectVirus Activation
dc.titleNew perspectives for preventing hepatitis C virus liver graft infection
dc.typejournal-article
dc.typeReview
plymouth.author-urlhttps://www.ncbi.nlm.nih.gov/pubmed/27301929
plymouth.issue6
plymouth.volume16
plymouth.publisher-urlhttp://dx.doi.org/10.1016/s1473-3099(16)00120-1
plymouth.publication-statusPublished
plymouth.journalThe Lancet Infectious Diseases
dc.identifier.doi10.1016/S1473-3099(16)00120-1
plymouth.organisational-group/Plymouth
plymouth.organisational-group/Plymouth/Faculty of Health
plymouth.organisational-group/Plymouth/Faculty of Health/Peninsula Medical School
plymouth.organisational-group/Plymouth/REF 2021 Researchers by UoA
plymouth.organisational-group/Plymouth/REF 2021 Researchers by UoA/UoA01 Clinical Medicine
plymouth.organisational-group/Plymouth/Users by role
plymouth.organisational-group/Plymouth/Users by role/Academics
dc.publisher.placeUnited States
dcterms.dateAccepted2016-02-15
dc.identifier.eissn1474-4457
dc.rights.embargoperiodNot known
rioxxterms.versionofrecord10.1016/S1473-3099(16)00120-1
rioxxterms.licenseref.urihttp://www.rioxx.net/licenses/all-rights-reserved
rioxxterms.licenseref.startdate2016-06
rioxxterms.typeJournal Article/Review


Files in this item

Thumbnail
Thumbnail

This item appears in the following Collection(s)

Show simple item record


All items in PEARL are protected by copyright law.
Author manuscripts deposited to comply with open access mandates are made available in accordance with publisher policies. Please cite only the published version using the details provided on the item record or document. In the absence of an open licence (e.g. Creative Commons), permissions for further reuse of content should be sought from the publisher or author.
Theme by 
Atmire NV